Open Access Research article

Management of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: an observational study

Stavros Liatis1*, Stavroula Papaoikonomou1, Asimina Ganotopoulou3, Athanasia Papazafiropoulou2, Constantinos Dinos1, Marios Michail1, Apostolos Xilomenos1, Andreas Melidonis3 and Stavros Pappas2

Author Affiliations

1 First Department of Propaedeutic Medicine, Diabetes Center, Athens University Medical School, Laiko Hospital, Ag. Thoma 17, 11527 Athens, Greece

2 Diabetes Center, Nikaia Hospital, Piraeus, Greece

3 Diabetes Center, Tzanio Hospital, Piraeus, Greece

For all author emails, please log on.

BMC Endocrine Disorders 2014, 14:23  doi:10.1186/1472-6823-14-23

Published: 5 March 2014



The aim of the present study is to examine the clinical indices related to cardiovascular risk management of Greek patients with type 2 diabetes, before and after the major economic crisis that emerged in the country.


In this retrospective database study, the medical records of patients with type 2 diabetes treated at three diabetes outpatient centers of the national health system during 2006 and 2012 were examined. Only patients with at least six months of follow-up prior to the recorded examination were included. The prescription cost was calculated in Euros per patient-year (€PY).


A total of 1953 medical records (938 from 2006 and 1015 from 2012) were included. There were no significant differences in adjusted HbA1c, systolic blood pressure and HDL-C, while significant reductions were observed in LDL-C and triglycerides. In 2012, a higher proportion of patients were prescribed glucose-lowering, lipid-lowering and antihypertensive medications. Almost 4 out of 10 patients were prescribed the new incretin-based medications, while the use of older drugs, except for metformin, decreased. A significant increase in the adjusted glucose-lowering prescription cost (612.4 [586.5-638.2] €PY vs 390.7 [363.5-418.0]; p < 0.001) and total prescription cost (1306.7 [1264.6-1348.7] €PY vs 1122.3[1078.1-1166.5]; p < 0.001) was observed. The cost of antihypertensive prescriptions declined, while no difference was observed for lipid-lowering and antiplatelet agents.


During the economic crisis, the cardiovascular risk indices of Greek patients with type 2 diabetes being followed in public outpatient diabetes clinics did not deteriorate and in the case of lipid profile improved. However, the total prescription cost increased, mainly due to the higher cost of glucose-lowering prescriptions.

Type 2 diabetes; Prescription cost; Economic crisis; Cardiovascular risk